Of the 99 samples with high-quality NGS data, 70 had no minority iSNV, 17 had one iSNV, 7 1 4 6 had two iSNV, and 3 samples had 3 iSNV (median 0, IQR 0-2; Table 2 ). Two outliers had a 1 4 7 large number of iSNV, with 8 and 20 iSNV. These two samples came from the same individual, 1 4 8 with one collected at home and the second at the study clinic. Most of the iSNV in these two 1 4 9 samples were present at similar frequencies, 3-5% and 17-23% in each specimen, respectively 1 5 0 (Table 3) , both of which were sequenced in duplicate on separate Illumina runs. The high 1 5 1 number of mutations present at similar frequencies is suggestive of a mixed infection with 1 5 2 distinct haplotypes or strains as opposed to de novo mutations arising on a single genetic 1 5 3 background. The iSNV in the home-collected sample are all found in the subsequent clinic-1 5 4 collected sample, each with a similar change in frequency across the two samples. This further 1 5 5 1 6 8 synonymous than nonsynonymous mutations, which given the ratio of synonymous and 1 6 9 nonsynonymous sites indicates that purifying selection dominates within hosts. There was only 1 7 0 one minority iSNV present in more than one individual; we identified a variant encoding a 1 7 1 synonymous mutation in PB1 in two individuals from separate households infected with 1 7 2 B/Yamagata in the 2016-2017 season. We did not identify any nonsynonymous minority iSNV in 1 7 3 the known antigenic sites of IBV hemagglutinin, which suggests that positive selective pressure 1 7 4 for variants that escape antibody-mediated immunity is not particularly strong within hosts. We 1 7 5 found that there is no difference in the distribution of the number of iSNV per sample between 1 7 6 vaccinated and non-vaccinated individuals ( Figure 4A ). During the first few seasons of the 1 7 7 study, some individuals received trivalent vaccines, which contain only one of the two IBV 1 7 8 lineages. We therefore repeated this analysis, excluding 3 individuals for whom we had no 1 7 9 information about specific vaccine product and re-classifying 6 individuals who received trivalent 1 8 0 vaccines and were infected with a lineage not included in that season's trivalent formulation as 1 8 1 "unvaccinated." We again found no difference in the number of iSNV between groups (MWU 1 8 2 test, p = 0.9103). Together, these data indicate that vaccine-induced immunity is not a major 1 8 3 diversifying force for IBV within hosts in our study population. This is consistent with our 1 8 4 previous work on IAV in the HIVE as well as a randomized-controlled trial of vaccine efficacy 1 8 5 (FLU-VACS), both of which showed no difference in intrahost diversity based on same-season 1 8 6 vaccination status (19, 20) . Intrahost diversity was similar between B/Victoria and B/Yamagata We compared the within-host genetic diversity of IBV to our previously published data on IAV 1 9 1 from the HIVE cohort (19) . Here, IBV exhibits lower within-host diversity compared to IAV 1 9 2 ( Figure 4C ). To ensure our results were not an artifact of overly stringent quality thresholds, we 1 9 3 also identified minority iSNV with less conservative read mapping quality (MapQ) and base 1 9 4 quality (Phred) scores. We identified the same set of minority iSNV with a MapQ cut-off of 20 as 1 9 5 with the original cutoff of 30. Similarly, reduction of the Phred base-quality cutoff to >25 in 1 9 6 addition to a MapQ score cutoff of >20 resulted in only 20 more minority iSNV, eight of which 1 9 7 were found in the individual with a mixed infection. The other additional 12 minority iSNV were 1 9 8 dispersed across specimens and did not significantly change the overall distribution of within-1 9 9 host diversity. We also examined whether our results were biased by use of a single 2 0 0 B/Yamagata and B/Victoria reference for alignment and variant calling, which were both drawn 2 0 1 from the 2012-2013 season (see Materials and Methods). We realigned sequence data from 43 2 0 2 of the original 99 samples to season-specific reference genomes isolated in southeastern 2 0 3
Michigan. We found that the overall alignment rate for any given specimen was similar between 2 0 4 the original reference and the new season-matched reference. Variant identification based on 2 0 5 the new references and the original quality thresholds resulted in the same distribution of within-2 0 6 host diversity, although the identity of some iSNV was different ( Figure 4D ). 2 0 7 9 2 0 8
Together, these results indicate that our measurements of within-host diversity are robust to 2 0 9 several technical aspects of variant identification and are unlikely to account for the lower 2 1 0 observed diversity of IBV. Because these data are from the same cohort and were generated 2 1 1 using the same sequencing approach and analytic pipeline as our previous IAV datasets, the 2 1 2 observed differences likely reflect true biological differences between IAV and IBV. We compared viral diversity across samples from individuals in the same household to 2 1 7 investigate the genetic bottleneck that influenza B viruses experience during natural 2 1 8 transmission. Over the seven influenza seasons, thirty-nine households in the HIVE cohort had 2 1 9 two or more individuals positive for the same IBV lineage within a 7-day interval (Table 1) . This 2 2 0 epidemiologic linkage is suggestive of transmission events but does not rule out co-incident 2 2 1 community acquired infection (19) . We identified 16 putative transmission pairs for which we 2 2 2 sequenced at least one sample from each individual. In one of these pairs, the putative recipient 2 2 3 was the individual with a mixed infection. The donor did not have evidence of a mixed infection 2 2 4 based on number of iSNV, which would imply that the recipient may have been infected twice or 2 2 5 that the second virus was lost from the donor by the time of sampling. This pair was excluded 2 2 6 from the between-host analysis, leaving 15 putative transmission pairs for which we have high-2 2 7 quality sequencing data on both donor and recipient influenza populations. We used our sequencing data to determine which of these epidemiologically linked household 2 3 0 pairs were actual IBV transmission pairs. We generated maximum likelihood phylogenetic trees 2 3 1 for samples from the two IBV lineages using the concatenated coding consensus sequences. Transmission bottlenecks restrict the genetic diversity that is passed between hosts. With a 2 5 1 loose transmission bottleneck, many unique genomes will be passed from donor to recipient.
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Because this will allow two variants at a given site to be transmitted, sites that are polymorphic 2 5 3 in the donor are more likely to be polymorphic in the recipient. However, in the case of a tight or 2 5 4 stringent bottleneck, sites that are polymorphic in the donor will likely be either fixed or absent in 2 5 5 the recipient. We have previously demonstrated that influenza A experiences a tight 2 5 6 transmission bottleneck of 1-2 unique genomes (19). Across our 15 IBV transmission pairs, we 2 5 7 found no sites that were polymorphic in the donor and recipient ( Figure 6 ). Intrahost SNV 2 5 8 present in the donor were either fixed (100%) or absent (0%) in the recipient. These data 12 individual level, with selection only evident over a broader scale of time and space (19, 35) . We 2 8 6 recognize, however, that it is possible for individual level selective pressure to vary in magnitude 2 8 7 by age, locale, influenza infection history, or immune status (36).
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We do find that there are important differences in the within-host evolution of IAV and IBV. IBV 2 9 0 displays significantly lower within-host diversity compared to IAV. Since measurements of 2 9 1 within-host diversity can vary based on host population, sequencing approach, and variant 2 9 2 calling algorithm (37), a strength of our study is that our comparison is based on samples from 2 9 3 the same cohort with the same sequencing approach and analytic pipeline. In both of our 2 9 4 studies, we have sequenced swab samples directly without prior culture, accounted for the 2 9 5 confounding effect of viral load, and used a standardized, empirically-validated analytic pipeline 2 9 6 for variant identification (23). This pipeline includes rigorous quality criteria to reduce false 2 9 7 positives that can be introduced by amplification and Illumina sequencing. Importantly, these 2 9 8 empirical quality criteria did not mask diversity actually present in these samples, strengthening 2 9 9 the conclusion that IBV exhibits lower within-host diversity compared to IAV.
The most likely biological explanation for IBV's lower within-host diversity is its de novo mutation 3 0 2 rate, which is thought to be at least two-fold lower than that of IAV (15). Viral mutation rates are 3 0 3 critical to the diversification of rapidly evolving viruses within hosts. Under a neutral model, the 3 0 4 number and frequency of minority variants is dependent on the mutation rate and demographics 3 0 5 of the population (16). In such a model, the expected number of variants is highly sensitive to 3 0 6 variation in the mutation rate across the range commonly estimated in RNA viruses. In light of 3 0 7 our results, a more thorough comparison of mutation rates across influenza viruses is needed. Another possible factor underlying IBV's reduced diversity is the mutational robustness of the 3 1 0 IBV genome relative to IAV. If IBV were less robust to mutation, stronger negative selection on 3 1 1 13 multiple genes in IBV could result in more limited within-host diversity, perhaps located to 3 1 2 certain regions of the genome. However, we found that the distributions of iSNV across IAV and 3 1 3 IBV genomes are relatively similar. Furthermore, we have previously shown that the distribution 3 1 4 of mutational fitness effects in influenza A/WSN/33/H1N1 matches that of other RNA and 3 1 5 ssDNA viruses (38) . Given that viruses across families with vastly different genomic architecture 3 1 6 have similar mutational robustness, this is unlikely to account for the differences in within-host 3 1 7 diversity between IAV and IBV. We find that IBV experiences a stringent genetic bottleneck between hosts. A stringent 3 2 0 transmission bottleneck places a constraint on the rate of adaptation of viral populations within 3 2 1 and between individual hosts. Population bottlenecks reduce the effective population size, which 3 2 2 increases random genetic drift and decreases the efficiency of selection (39). This results in a 3 2 3 reduced ability of selection to fix beneficial mutations and to remove deleterious ones, which 3 2 4
can decrease population fitness. However, there are potential evolutionary advantages to 3 2 5 stringent bottlenecks, including removal of defective interfering particles (40,41). While we were 3 2 6 not able to estimate the size of the transmission bottleneck as precisely as IAV, it is likely that 3 2 7 the bottleneck size is comparable across the two viruses given the similarities in their 3 2 8 transmission routes and ecology in the human population. Data from many more transmission 3 2 9 pairs will be necessary for a more robust estimate.
Together, our results are consistent with the slower rate of global evolution observed in IBV 3 3 2 lineages compared with both seasonal A/H1N1 and A/H3N2 (10, 12, 14, 42) . We suggest that a Intrahost single-nucleotide variants (iSNV) were identified using a previously-described analytic 4 1 1 pipeline (23). We identified iSNV in samples that had an average genome coverage greater 17 aligned to the sequences derived from the B/Victoria and B/Yamagata plasmid controls with 4 1 5 Bowtie2 (32). Duplicate reads were marked and removed with Picard and samtools (33).
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Putative variants were identified with the R package deepSNV using data from the clonal 4 1 7 plasmid controls of each sequencing run (34). Minority iSNV (<50% frequency) were identified 4 1 8 using the following empirically-derived criteria: deepSNV p-value <0.01, average mapping In our previous work on IAV, we found that there were multiple sites with mutations that were 4 2 7 essentially fixed (>0.95) relative to the plasmid control and in which the base in the plasmid 4 2 8 control was therefore identified as a minority variant in the sample (19) . At these sites, deepSNV 4 2 9 is unable to estimate the base-specific error rate and cannot distinguish true minority iSNV; 4 3 0 however, we found that we could accurately identify minority variants at these sites at a 4 3 1 frequency of 2% or above (19) (inferred based on day of symptom onset). Each iSNV is plotted as a point with its frequency in 6 1 5 the recipient (y-axis) versus its frequency in the donor (x-axis). 6 1 6 Table 1 -2011 2011-2012 2012-2013 2013-2014 2014-2015 2015-2016 2016-2017 Households  328  213  321  232  340  227  208  Participants  1441  943  1426  1049  1431  996 
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